HUP0402492A2 - 5HT4 részleges agonistát tartalmazó gyógyszerkészítmények - Google Patents

5HT4 részleges agonistát tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0402492A2
HUP0402492A2 HU0402492A HUP0402492A HUP0402492A2 HU P0402492 A2 HUP0402492 A2 HU P0402492A2 HU 0402492 A HU0402492 A HU 0402492A HU P0402492 A HUP0402492 A HU P0402492A HU P0402492 A2 HUP0402492 A2 HU P0402492A2
Authority
HU
Hungary
Prior art keywords
partial agonist
weight
pharmaceutical compositions
amount
agonist pharmaceutical
Prior art date
Application number
HU0402492A
Other languages
English (en)
Inventor
Jérome Aubert
Christian Vitzling
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of HUP0402492A2 publication Critical patent/HUP0402492A2/hu
Publication of HUP0402492A3 publication Critical patent/HUP0402492A3/hu
Publication of HU226589B1 publication Critical patent/HU226589B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A találmány orális adagolásra alkalmas, szilárd gyógyászatikészítményre vonatkozik, amely 5HT4 részleges agonistát, példáultegaserodot bázis vagy só formában, legfeljebb 10 tömeg% mennyiségben,egy térfogatnövelő szert 70-90 tömeg% mennyiségben, széteséstelősegítő anyagot 15 tömeg%-nál kisebb mennyiségben, gördülékenységetnövelő anyagot és kenőanyagot tartalmaz. A találmány tárgyát képeziktovábbá, a gyógyászati készítmények előállítására alkalmas eljárásokis. Ó
HU0402492A 2001-12-21 2002-12-20 Tegaserod pharmaceutical compositions HU226589B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01403339A EP1321142A1 (en) 2001-12-21 2001-12-21 Solid pharmaceutical composition for oral administration of Tegaserod
PCT/EP2002/014674 WO2003053432A1 (en) 2001-12-21 2002-12-20 5ht4 partial agonist pharmaceutical compositions

Publications (3)

Publication Number Publication Date
HUP0402492A2 true HUP0402492A2 (hu) 2005-07-28
HUP0402492A3 HUP0402492A3 (en) 2008-04-28
HU226589B1 HU226589B1 (en) 2009-04-28

Family

ID=8183045

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402492A HU226589B1 (en) 2001-12-21 2002-12-20 Tegaserod pharmaceutical compositions

Country Status (31)

Country Link
US (2) US20050106236A1 (hu)
EP (2) EP1321142A1 (hu)
JP (1) JP4718776B2 (hu)
KR (1) KR100980144B1 (hu)
CN (1) CN100464749C (hu)
AR (1) AR037937A1 (hu)
AT (1) ATE320807T1 (hu)
AU (1) AU2002361198B2 (hu)
BR (1) BR0215148A (hu)
CA (1) CA2470668C (hu)
CO (1) CO5640102A2 (hu)
CY (1) CY1105559T1 (hu)
DE (1) DE60210139T2 (hu)
DK (1) DK1458377T3 (hu)
EC (1) ECSP105163A (hu)
EG (1) EG24194A (hu)
ES (1) ES2258171T3 (hu)
HU (1) HU226589B1 (hu)
IL (2) IL162451A0 (hu)
MX (1) MXPA04006157A (hu)
MY (1) MY139546A (hu)
NO (1) NO20042779L (hu)
NZ (1) NZ533585A (hu)
PE (1) PE20030872A1 (hu)
PL (1) PL369509A1 (hu)
PT (1) PT1458377E (hu)
RU (1) RU2322978C2 (hu)
SI (1) SI1458377T1 (hu)
TW (1) TWI260221B (hu)
WO (1) WO2003053432A1 (hu)
ZA (1) ZA200404467B (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL200132B1 (pl) * 1998-08-21 2008-12-31 Novartis Ag Zastosowanie 3-(5-metoksy-1H-indol-3-ilometyleno)-N-pentylokarbazyimidoamidu
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1911763B1 (en) 2003-01-28 2010-08-11 Ironwood Pharmaceuticals, Inc. Compositions for the treatment of gastrointestinal disorders
WO2004085393A1 (en) * 2003-03-25 2004-10-07 Hetero Drugs Limited Novel crystalline forms of tegaserod maleate
EP1629280A2 (en) * 2003-05-21 2006-03-01 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
PE20050253A1 (es) * 2003-07-24 2005-06-03 Novartis Ag Modificaciones estables de maleato de hidrogeno de tegaserod
EP1663182B2 (en) 2003-09-12 2019-11-20 Amgen Inc. RAPID DISSOLUTION FORMULATION OF CINACALCET HCl
WO2005058819A2 (en) * 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Polymorphic forms of tegaserod base and salts thereof
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2748607A1 (en) 2008-12-31 2010-07-08 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
AU2013304812B2 (en) 2012-08-21 2016-06-09 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
PT2983667T (pt) 2013-04-12 2019-07-11 Ardelyx Inc Compostos e métodos de ligação ao nhe3 para inibir o transporte de fosfato
CN104922083B (zh) * 2015-04-15 2017-12-22 湖南尔康湘药制药有限公司 磺胺嘧啶片及其制备方法
EA036204B1 (ru) * 2015-10-16 2020-10-14 Нобел Илач Санайи Ве Тиджарет А.Ш. Фармацевтические композиции нилотиниба гидрохлорида
BR112019013963A2 (pt) 2017-01-09 2020-04-28 Ardelyx Inc inibidores de antiporte mediado por nhe
US11242337B2 (en) 2017-01-09 2022-02-08 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0820586A (ja) * 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
PL200132B1 (pl) * 1998-08-21 2008-12-31 Novartis Ag Zastosowanie 3-(5-metoksy-1H-indol-3-ilometyleno)-N-pentylokarbazyimidoamidu
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
PL199137B1 (pl) * 1999-08-03 2008-08-29 Lilly Icos Llc Kompozycja farmaceutyczna pochodnej ß-karboliny i jej zastosowanie terapeutyczne

Also Published As

Publication number Publication date
ES2258171T3 (es) 2006-08-16
CN100464749C (zh) 2009-03-04
RU2004122631A (ru) 2005-08-10
AR037937A1 (es) 2004-12-22
JP2005516946A (ja) 2005-06-09
DE60210139D1 (de) 2006-05-11
WO2003053432A1 (en) 2003-07-03
TW200410684A (en) 2004-07-01
BR0215148A (pt) 2004-10-19
EG24194A (en) 2008-10-14
MXPA04006157A (es) 2004-10-27
PT1458377E (pt) 2006-07-31
US20050106236A1 (en) 2005-05-19
NO20042779L (no) 2004-09-17
HU226589B1 (en) 2009-04-28
DE60210139T2 (de) 2006-08-17
NZ533585A (en) 2006-04-28
MY139546A (en) 2009-10-30
EP1321142A1 (en) 2003-06-25
AU2002361198B2 (en) 2006-06-08
EP1458377A1 (en) 2004-09-22
IL162451A0 (en) 2005-11-20
CY1105559T1 (el) 2010-07-28
IL162451A (en) 2009-02-11
ZA200404467B (en) 2006-05-31
CO5640102A2 (es) 2006-05-31
CA2470668C (en) 2011-07-05
ECSP105163A (es) 2010-07-30
EP1458377B1 (en) 2006-03-22
TWI260221B (en) 2006-08-21
HUP0402492A3 (en) 2008-04-28
SI1458377T1 (sl) 2006-08-31
KR20040066922A (ko) 2004-07-27
PL369509A1 (en) 2005-04-18
US20090104263A1 (en) 2009-04-23
ATE320807T1 (de) 2006-04-15
KR100980144B1 (ko) 2010-09-03
JP4718776B2 (ja) 2011-07-06
PE20030872A1 (es) 2003-11-24
CN1606438A (zh) 2005-04-13
DK1458377T3 (da) 2006-06-12
AU2002361198A1 (en) 2003-07-09
RU2322978C2 (ru) 2008-04-27
CA2470668A1 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
HUP0402492A2 (hu) 5HT4 részleges agonistát tartalmazó gyógyszerkészítmények
HK1076605A1 (en) Formulations
HUP0203176A2 (hu) Szimetikont tartalmazó orális, szilárd adagolási forma
HUP0101411A2 (hu) 2-es típusú angiotenzin II receptor agonistákat tartalmazó gyógyszerkészítmények és ezek alkalmazása
WO2004000197A3 (en) Quick dissolve compositions and tablets based thereon
NO20053143L (no) Farmasoytiske sammensetninger omfattende en basisk, henholdsvis sur legemiddelforbindelse, en sufaktant og en fysiologisk akseptabel vannloselig syre henholdsvis base.
HUP0301972A2 (hu) Fentanilszerű szerkezetű opioidot és ketamint tartalmazó hatóanyag-kombináció és ezt tartalmazó gyógyszerkészítmény
HUP0102160A2 (hu) Alfa-keto-enamin-származékok alkalmazása alkotórészként
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
HUP0002316A2 (hu) Gyorsan olvadó orális adagolási formák
BG108420A (en) New indole derivatives with 5-ht6 receptor affinity
MXPA04007414A (es) Indoles sustituidos como agonistas alfa-1.
MEP49308A (en) Once-a-day oxycodone formulations
HUP0100156A2 (hu) Foszfolipáz-A2 inhibitor hatású indolszármazékok és alkalmazásuk gyógyászati készítmények előállítására
ATE286500T1 (de) 1,2,3,4-tetrahydroisochinolin-derivate
SE0302760D0 (sv) New compounds
HUP0204451A2 (hu) Nimesulidot tartalmazó szabályozott hatóanyag-leadású készítmények
HK1070054A1 (en) Arylsulfonyl derivatives with5-ht6 receptor affinity
HUP0103454A2 (hu) Entacapont vagy nitecapont és keresztkötésű cellulózszármazékot tartalmazó gyógyászati készítmény
IL119989A0 (en) Pharmaceutical compositions for oral treatment of multiple sclerosis
HUP0301349A2 (hu) IL-11-tartalmú készítmények
HUP0103431A2 (hu) 5-HT4 receptor agonista vagy antagonista hatóanyagot tartalmazó, orális gyógyászati készítmény
HUP0301390A2 (hu) Valzartánt tartalmazó orális gyógyászati készítmény
NO20034863L (no) Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser
HUP0105308A2 (hu) Eletriptán-hidrobromid-monohidrát, eljárás az előállítására és a vegyületet tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees